Companion Nutrition:
dietary strategies for the age of GLP-1

1. The GLP-1 era: a pharmacological revolution without nutritional precedent

2026 is the year in which GLP-1 drugs — glucagon-like peptide-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have become a global public health phenomenon. Approximately 12% of American adults have already used these molecules; in Europe, uptake is growing rapidly, driven by the institutional recognition of obesity as a chronic condition requiring long-term pharmacological treatment.

The efficacy of GLP-1s in reducing body weight — with documented losses of 10–20% in controlled clinical trials — has radically shifted the paradigm of obesity management. But pharmacological efficacy does not automatically resolve the nutritional challenge: if anything, it complicates it. When one eats less — and with GLP-1s, one eats significantly less — every calorie must work much harder.

From this awareness emerges companion nutrition: the specific nutritional discipline for those using GLP-1 therapies, focused not on the quantity of food but on its composition — to prevent the loss of lean mass, manage gastrointestinal side effects, and ensure adequate coverage of essential micronutrients within a reduced caloric intake.

"GLP-1s silence the noise of food. Companion nutrition teaches us to make the few remaining words count."

2. The silent risk: lean mass loss and sarcopenia

The visible success of GLP-1s — rapid and significant weight loss — conceals a less obvious but metabolically critical risk: the loss of muscle mass. When the caloric balance becomes strongly negative due to drug-induced appetite suppression, the body does not draw exclusively on adipose tissue. It also mobilises muscle proteins to sustain energy requirements — a process that, in the absence of countermeasures, can erode up to 40% of total weight loss by attributing it to lean mass rather than fat.

Muscle mass loss is not merely an aesthetic problem. It is a long-term metabolic one: muscle is the body's primary insulin-sensitive tissue, the principal site of glucose uptake, and the engine of basal metabolism. A person who loses weight by reducing muscle mass ends up with a slower and more insulin-resistant metabolism than before — precisely the opposite of the therapy's goal.

This phenomenon — known as "sarcopenic obesity" when it involves people with excess weight — is the principal driver of companion nutrition: the need to build a specific nutritional strategy that protects muscle while GLP-1 works on fat.

3. Protein as a clinical strategy: requirements and sources

The leading scientific societies — the American College of Lifestyle Medicine, the American Society for Nutrition, and the Obesity Medicine Association — published a joint advisory in 2025 that sets protein recommendations for GLP-1 patients far more precisely than general guidelines. The recommended target is 1.2–1.6 g per kg of adjusted body weight per day, with some clinicians aiming for 1.5 g per kg of fat-free mass (FFM) as a more accurate parameter. In practical terms, this translates into a daily protein target of 80–120 g for most adults.

The challenge is that GLP-1s reduce appetite non-selectively: patients eat less of everything, including protein. Nausea — a frequent side effect in the first weeks — can make consuming solid protein sources particularly difficult, as these tend to be "heavier" to digest than refined carbohydrates. The paradox of GLP-1 companion nutrition is that the moment when protein requirements are highest coincides with the moment when consuming protein is most difficult.

The most recommended protein sources in GLP-1 protocols are those with high amino acid density and high gastric tolerability: Greek yogurt, eggs, tofu and tempeh, white fish, cottage cheese, bone broth. Protein shakes and high-protein smoothies with fruit and vegetables become valuable tools during phases of intense nausea, ensuring the target is met without requiring high food volumes.

4. Fibre and prebiotics for gastrointestinal tolerability

The gastrointestinal side effects of GLP-1s — nausea, constipation, diarrhoea, gastro-oesophageal reflux — are the leading cause of therapy discontinuation in the first weeks. Nutritional management of these effects is not supplementary: it is often decisive for completing the drug titration and for long-term treatment adherence.

Constipation is the most common symptom: GLP-1s slow gastric emptying and intestinal motility, reducing transit frequency. Dietary fibres — especially soluble ones that form viscous gels and retain water — are the first line of nutritional intervention. But the GLP-1 context requires a clarification: fibre intake must be gradual and well hydrated. A sudden increase in an already drug-slowed digestive system can worsen bloating and discomfort.

Clinically tested prebiotics — such as enzymatically fermented guar (Sunfiber), acacia fibre, and psyllium — have the most favourable tolerability profile in the GLP-1 context: they ferment slowly in the colon without producing excess gas, lubricate transit, and nourish the microbiome without overloading an already stressed digestive system.

5. Micronutrients at risk: the deficiency profile of GLP-1 patients

Unlike bariatric surgery, GLP-1s do not cause intestinal malabsorption. But the net effect on micronutrient deficiency risk is similar: when total caloric intake drops significantly, so does the intake of vitamins, minerals, and trace elements, regardless of the quality of food chosen. Guidelines published in the International Journal of Obesity in 2026 identify the typical GLP-1 patient deficiency profile with a precision that is leading many clinicians to adopt systematic supplementation protocols.

The micronutrients most frequently at risk are: vitamin B12 (reduced consumption of meat and dairy lowers dietary intake, while metformin — often co-prescribed — further reduces absorption), vitamin D (fat mass loss can paradoxically reduce available vitamin D, which is fat-soluble and accumulates in adipose tissue), calcium (critical for preventing bone loss associated with rapid weight reduction), and iron and zinc (immunological micronutrients whose intake decreases proportionally with the drop in animal protein consumption).

6. The proteinification of food: a response to need or a market distortion?

2026 has established protein as the "new reference macronutrient" for food marketing. Protein snacks, high-protein bread, breakfast cereals with 15 g of protein per serving, protein ice cream, even protein crisps: "proteinification" has reached virtually every consumer goods category. In the UK, 47.5% of consumers have actively tried to increase their protein intake over the past three months. In the United States, products with protein claims are growing at a CAGR of 7%, four times higher than products without claims.

This trend was directly accelerated by the spread of GLP-1s: public awareness of the muscle loss risk — amplified by "Ozempic face" images on social media — created market demand for foods promising to protect muscle while losing weight. The food industry responded with speed and its usual marketing logic: adding protein to products that had none — or that did not need it.

The problem is that industrial "proteinification" is not necessarily synonymous with nutritional quality. A biscuit with 10 g of whey protein remains a biscuit — with refined sugar, saturated fats, and a glycaemic profile that contradicts the metabolic objectives of the GLP-1 patient. The added protein does not neutralise the food matrix: it coexists with it.

"Adding protein to an ultra-processed product does not turn it into a functional food. It turns it into an ultra-processed product with more protein."

7. The value of whole foods in the maintenance phase

The maintenance phase — the one following the achievement of the weight target, when GLP-1 therapy is suspended or reduced — is the most critical for long-term metabolic outcomes. The research is unequivocal: most of the weight regained after GLP-1 discontinuation is lean mass and fat, and regain occurs more rapidly if sustainable whole-food eating habits were not built during the therapy.

Whole, minimally processed foods have characteristics that industrially proteinified products cannot replicate by addition: the synergy of natural components — fibres, polyphenols, micronutrients, proteins, and fats co-present in the original matrix — produces metabolic effects that no reformulated product can fully imitate. A whole legume has different — and better — effects than a legume protein isolate.

The guidelines of the leading scientific societies converge on this point: the diet supporting GLP-1s must emphasise a variety of nutrient-dense, minimally processed foods — fruits, vegetables, whole grains, legumes, lean proteins, nuts, and seeds. Not as an aesthetic goal, but as a long-term metabolic strategy.

8. Companion nutrition in daily practice

The theory of companion nutrition runs into a practical reality: with appetite reduced by the medication, the last thing patients want to navigate is the complexity of an elaborate diet. Effective companion nutrition must by definition be simple, adaptable, and nutrient-dense per volume — not the volume of a normal diet, but the quality of nutrients in every bite consumed.

Operational principles of GLP-1 companion nutrition

• 01
  Protein first: every meal starts with protein
  With reduced appetite, the risk is that the protein portion gets skipped in favour of "easier" carbohydrates. The operational rule: at every meal, protein is eaten first — Greek yogurt, egg, legumes — and only then come carbohydrates and vegetables.
• 02
  Protein shake as plan B: always on hand
  On days of intense nausea or near-absent appetite, a protein smoothie with fruit, vegetables, and a protein source is the plan B that ensures the target is met without requiring excessive digestive effort. It should be prepared before symptoms appear.
• 03
  Low-fermentation fibres: gradual increase and hydration
  Fibres are introduced gradually — never a sudden increase — and always accompanied by at least 250–500 ml of additional water. Soluble fibre sachets should be taken away from main protein meals to avoid interfering with amino acid absorption.
• 04
  Micronutrients in powder or drink form: better tolerated
  Bulky capsules and tablets can increase the sense of nausea in GLP-1 patients. Powder forms dissolved in water — sachets, drinks — are generally better tolerated during phases of heightened gastric sensitivity.
• 05
  Quarterly monitoring of body composition
  Scale weight is an insufficient indicator during GLP-1 therapy. Measuring lean mass (DXA, bioelectrical impedance) every 2–3 months allows verification that weight loss is compositionally favourable — and that muscle is not being lost alongside fat.

9. The GLP-1 companion nutrition protocol: 5 layers

Effective companion nutrition is structured in overlapping layers, each with a specific role in the context of GLP-1 therapy. It is not necessary to implement all of them simultaneously: one starts from the foundational layers and adds the subsequent ones as the therapy stabilises.